Drug
Encaleret
Encaleret: highest development phase Phase 3, developed by Calcilytix Therapeutics, Inc., a BridgeBio company. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Calcilytix Therapeutics, Inc., a BridgeBio company
Trials
| Drug | Phase | Indication |
|---|---|---|
| Encaleret NCT07805356 | Phase 3 | Hypoparathyroidism |
Latest
No recent events.
Follow Encaleret on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.